Selected research
Industry Research
Respiratory Syncytial Virus Vaccine for Children Industry Research Report 2026
Market perspective
The global Respiratory Syncytial Virus Vaccine for Children market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Respiratory Syncytial Virus Vaccine for Children is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Respiratory Syncytial Virus Vaccine for Children is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Respiratory Syncytial Virus Vaccine for Children include Clover Biopharma, Advaccine, Wits Health Consortium (Pty) Ltd, Sanofi, Pfizer, Novavax, Moderna, Meissa and Codagenix, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Respiratory Syncytial Virus Vaccine for Children market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Respiratory Syncytial Virus Vaccine for Children Market by Company
Clover Biopharma
Advaccine
Wits Health Consortium (Pty) Ltd
Sanofi
Pfizer
Novavax
Moderna
Meissa
Codagenix
Blue Lake Biotechnology
Respiratory Syncytial Virus Vaccine for Children Segment by Type
Recombinant Protein Vaccine
Nucleic Acid Vaccine
Others
Respiratory Syncytial Virus Vaccine for Children Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Respiratory Syncytial Virus Vaccine for Children Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for Children market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for Children and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for Children.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for Children manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Respiratory Syncytial Virus Vaccine for Children by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Respiratory Syncytial Virus Vaccine for Children in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Protein Vaccine
- Nucleic Acid Vaccine
- Others
Applications
- Hospital
- Centers for Disease Control and Prevention
- Others
Companies covered
- Clover Biopharma
- Advaccine
- Wits Health Consortium (Pty) Ltd
- Sanofi
- Pfizer
- Novavax
- Moderna
- Meissa
- Codagenix
- Blue Lake Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Respiratory Syncytial Virus Vaccine for Children Market Size (2021-2032)
- 2.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales (2021-2032)
- 2.2.3 Global Respiratory Syncytial Virus Vaccine for Children Market Average Price (2021-2032)
- 2.3 Respiratory Syncytial Virus Vaccine for Children by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Recombinant Protein Vaccine
- 2.3.3 Nucleic Acid Vaccine
- 2.3.4 Others
- 2.4 Respiratory Syncytial Virus Vaccine for Children by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Centers for Disease Control and Prevention
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Respiratory Syncytial Virus Vaccine for Children Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Respiratory Syncytial Virus Vaccine for Children Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue of Manufacturers (2021-2026)
- 3.4 Global Respiratory Syncytial Virus Vaccine for Children Average Price by Manufacturers (2021-2026)
- 3.5 Global Respiratory Syncytial Virus Vaccine for Children Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Respiratory Syncytial Virus Vaccine for Children, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Respiratory Syncytial Virus Vaccine for Children, Product Type & Application
- 3.8 Global Manufacturers of Respiratory Syncytial Virus Vaccine for Children, Established Date
- 3.9 Global Respiratory Syncytial Virus Vaccine for Children Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Clover Biopharma
- 4.1.1 Clover Biopharma Company Information
- 4.1.2 Clover Biopharma Business Overview
- 4.1.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.1.5 Clover Biopharma Recent Developments
- 4.2 Advaccine
- 4.2.1 Advaccine Company Information
- 4.2.2 Advaccine Business Overview
- 4.2.3 Advaccine Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Advaccine Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.2.5 Advaccine Recent Developments
- 4.3 Wits Health Consortium (Pty) Ltd
- 4.3.1 Wits Health Consortium (Pty) Ltd Company Information
- 4.3.2 Wits Health Consortium (Pty) Ltd Business Overview
- 4.3.3 Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.3.5 Wits Health Consortium (Pty) Ltd Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Novavax
- 4.6.1 Novavax Company Information
- 4.6.2 Novavax Business Overview
- 4.6.3 Novavax Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novavax Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.6.5 Novavax Recent Developments
- 4.7 Moderna
- 4.7.1 Moderna Company Information
- 4.7.2 Moderna Business Overview
- 4.7.3 Moderna Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Moderna Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.7.5 Moderna Recent Developments
- 4.8 Meissa
- 4.8.1 Meissa Company Information
- 4.8.2 Meissa Business Overview
- 4.8.3 Meissa Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Meissa Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.8.5 Meissa Recent Developments
- 4.9 Codagenix
- 4.9.1 Codagenix Company Information
- 4.9.2 Codagenix Business Overview
- 4.9.3 Codagenix Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Codagenix Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.9.5 Codagenix Recent Developments
- 4.10 Blue Lake Biotechnology
- 4.10.1 Blue Lake Biotechnology Company Information
- 4.10.2 Blue Lake Biotechnology Business Overview
- 4.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 4.10.5 Blue Lake Biotechnology Recent Developments
5 Global Respiratory Syncytial Virus Vaccine for Children Market Scenario by Region
- 5.1 Global Respiratory Syncytial Virus Vaccine for Children Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021-2032
- 5.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021-2026
- 5.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2027-2032
- 5.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region: 2021-2032
- 5.3.1 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region: 2021-2026
- 5.3.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region: 2027-2032
- 5.4 North America Respiratory Syncytial Virus Vaccine for Children Market Facts & Figures by Country
- 5.4.1 North America Respiratory Syncytial Virus Vaccine for Children Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 5.4.3 North America Respiratory Syncytial Virus Vaccine for Children Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Respiratory Syncytial Virus Vaccine for Children Market Facts & Figures by Country
- 5.5.1 Europe Respiratory Syncytial Virus Vaccine for Children Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 5.5.3 Europe Respiratory Syncytial Virus Vaccine for Children Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Respiratory Syncytial Virus Vaccine for Children Market Facts & Figures by Country
- 5.6.1 Asia Pacific Respiratory Syncytial Virus Vaccine for Children Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Respiratory Syncytial Virus Vaccine for Children Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Respiratory Syncytial Virus Vaccine for Children Market Facts & Figures by Country
- 5.7.1 South America Respiratory Syncytial Virus Vaccine for Children Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 5.7.3 South America Respiratory Syncytial Virus Vaccine for Children Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Type (2021-2032)
- 6.1.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Type (2021-2032)
- 6.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Type (2021-2032)
- 6.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue Market Share by Type (2021-2032)
- 6.3 Global Respiratory Syncytial Virus Vaccine for Children Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Application (2021-2032)
- 7.1.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Application (2021-2032)
- 7.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Application (2021-2032)
- 7.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue Market Share by Application (2021-2032)
- 7.3 Global Respiratory Syncytial Virus Vaccine for Children Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Respiratory Syncytial Virus Vaccine for Children Value Chain Analysis
- 8.1.1 Respiratory Syncytial Virus Vaccine for Children Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Respiratory Syncytial Virus Vaccine for Children Production Mode & Process
- 8.2 Respiratory Syncytial Virus Vaccine for Children Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Respiratory Syncytial Virus Vaccine for Children Distributors
- 8.2.3 Respiratory Syncytial Virus Vaccine for Children Customers
9 Global Respiratory Syncytial Virus Vaccine for Children Analyzing Market Dynamics
- 9.1 Respiratory Syncytial Virus Vaccine for Children Industry Trends
- 9.2 Respiratory Syncytial Virus Vaccine for Children Industry Drivers
- 9.3 Respiratory Syncytial Virus Vaccine for Children Industry Opportunities and Challenges
- 9.4 Respiratory Syncytial Virus Vaccine for Children Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst